FAQ/Help |
Calendar |
Search |
Today's Posts |
05-15-2008, 03:40 AM | #1 | |||
|
||||
Member
|
Proceed to www.neurologix.net and browse through their latest statement re their first quarter financials. Phase two trials must be close with this announcement......
John Mordock, President and Chief Executive Officer of Neurologix, noted that these first quarter financial results were consistent with the Company's expectations. "In March, we received authorization from the U.S. Food and Drug Administration for our planned Phase 2 clinical trial in Parkinson's disease," said Mr. Mordock. "This represents the crossing of a major hurdle for the development of our gene transfer approach to the treatment of this disease. We have been contracting with clinical sites and reviewing prospective trial subjects for this study, and expect to begin enrolling patients during the second quarter.
__________________
The true leaders of today are those who strive for a world where it's every citizen can enjoy the benefits of scientific enlightenment and technological progress. GO HARD>>>>SCIENCE Last edited by Howardh; 05-15-2008 at 06:31 AM. |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Have to share this article! Great News! | Gluten Sensitivity / Celiac Disease | |||
NEWS: Gene Therapy For Parkinson's Hitches Ride On Virus | Parkinson's Disease | |||
CBS news -gene therapy abit more info -video | Parkinson's Disease | |||
Great news for Ceregene (gene therapy) ... | Parkinson's Disease | |||
Great News!! | Thoracic Outlet Syndrome |